Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma

Lenvatinib was recently approved as a novel first-line molecular targeted agent (MTA) for treating hepatocellular carcinoma (HCC). The importance of relative dose intensity (RDI) has been shown in the treatment of various types of cancers. However, RDI may not accurately reflect the treatment intens...

Descripción completa

Detalles Bibliográficos
Autores principales: Eso, Yuji, Nakano, Shigeharu, Mishima, Masako, Arasawa, Soichi, Iguchi, Eriko, Nakamura, Fumiyasu, Takeda, Haruhiko, Takai, Atsushi, Takahashi, Ken, Taura, Kojiro, Seno, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016578/
https://www.ncbi.nlm.nih.gov/pubmed/31877859
http://dx.doi.org/10.3390/cancers12010049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016578/
https://www.ncbi.nlm.nih.gov/pubmed/31877859
http://dx.doi.org/10.3390/cancers12010049

Ejemplares similares